Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.58 |
| ▸ | MEN1 | O00255 | 7/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.54 |
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | XDH | P47989 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8737936 | 0.92 | MEN1 (0.56) | OPRM1MEN1KMT2AGAANPC1 | |
| SCHEMBL8738331 | 0.91 | OPRM1 (0.59) | OPRM1MEN1KMT2ATRPV4GAA | |
| SCHEMBL8737779 | 0.89 | MEN1 (0.59) | MEN1KMT2AGAARAB9AKDM4E | |
| SCHEMBL8738636 | 0.88 | OPRM1 (0.54) | OPRM1MEN1KMT2ATRPV4GAA | |
| SCHEMBL6114428 | 0.86 | MAPT (0.57) | OPRM1MEN1KMT2ATRPV4GAA | |
| SCHEMBL8737943 | 0.86 | OPRM1 (0.60) | OPRM1MEN1KMT2ATRPV4GAA | |
| SCHEMBL6114003 | 0.85 | MEN1 (0.63) | OPRM1MEN1KMT2ATRPV4GAA | |
| SCHEMBL8738391 | 0.85 | TDP1 (0.63) | OPRM1MEN1KMT2AGAANPC1 | |
| SCHEMBL8738330 | 0.84 | ALDH1A1 (0.42) | OPRM1MEN1KMT2AGAAKDM4E | |
| SCHEMBL8739106 | 0.84 | MAPT (0.67) | OPRM1MEN1KMT2ATRPV4GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120129842-A1 | BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129842-A1 | BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION | MMP1, MMP9, MMP2 | OPRM1 3274/4885MEN1 2298/4885KMT2A 2435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.